215 related articles for article (PubMed ID: 27358992)
1. [Domestication of suspension CHO cells and its application in the expression of anti-PSMA antibody].
Wu J; Han D; Wei M; Zheng G; Jiao D; Xi W; Yang A; Qin W; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jan; 32(1):1-4. PubMed ID: 27358992
[TBL] [Abstract][Full Text] [Related]
2. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
3. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
4. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells.
Schlatter S; Stansfield SH; Dinnis DM; Racher AJ; Birch JR; James DC
Biotechnol Prog; 2005; 21(1):122-33. PubMed ID: 15903249
[TBL] [Abstract][Full Text] [Related]
5. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
6. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
[TBL] [Abstract][Full Text] [Related]
7. [Rapid construction of a mammalian cell surface display library of full-length human antibodies].
He W; Li CZ; Chen ZR; Zhou Y; Tan WL; Jiang SB; Zhou ZG; Liu SW; Zhou C
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Feb; 31(2):308-12. PubMed ID: 21354918
[TBL] [Abstract][Full Text] [Related]
8. Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer.
Bühler P; Wetterauer D; Gierschner D; Wetterauer U; Beile UE; Wolf P
Anticancer Res; 2010 Sep; 30(9):3373-9. PubMed ID: 20944111
[TBL] [Abstract][Full Text] [Related]
9. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
[TBL] [Abstract][Full Text] [Related]
10. A simple method to determine IgG light chain to heavy chain polypeptide ratios expressed by CHO cells.
Gerster A; Wodarczyk C; Reichenbächer B; Köhler J; Schulze A; Krause F; Müller D
Biotechnol Lett; 2016 Dec; 38(12):2043-2049. PubMed ID: 27613153
[TBL] [Abstract][Full Text] [Related]
11. [Expression of chimeric anti-CD3 IgG antibody in mammalian cells and analysis of its biological activity].
Shao XF; Xu C; Xu YF; Xiong DS; Liu YX; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2003 Sep; 19(5):527-31. PubMed ID: 15969078
[TBL] [Abstract][Full Text] [Related]
12. Camel heavy chain antibodies against prostate-specific membrane antigen.
Evazalipour M; Tehrani BS; Abolhassani M; Morovvati H; Omidfar K
Hybridoma (Larchmt); 2012 Dec; 31(6):424-9. PubMed ID: 23244321
[TBL] [Abstract][Full Text] [Related]
13. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity.
Mason LJ; Lambrianides A; Haley JD; Manson JJ; Latchman DS; Isenberg DA; Rahman A
Arthritis Res Ther; 2005; 7(5):R971-83. PubMed ID: 16207338
[TBL] [Abstract][Full Text] [Related]
14. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.
Frigerio B; Benigni F; Luison E; Seregni E; Pascali C; Fracasso G; Morlino S; Valdagni R; Mezzanzanica D; Canevari S; Figini M
Immunol Lett; 2015 Nov; 168(1):105-10. PubMed ID: 26404855
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
[TBL] [Abstract][Full Text] [Related]
16. [Construction, expression, and identification of the gene of human anti-prostate specific membrane antigen single-chain antibody].
Su YS; Fu XL; Wang D; Wang QY; Liu N; Jia HB; Qin WJ; Wen WH; Wang H
Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1063-7. PubMed ID: 25597169
[TBL] [Abstract][Full Text] [Related]
17. A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.
Nawaz S; Mullen GED; Blower PJ; Ballinger JR
Nucl Med Commun; 2017 Aug; 38(8):666-671. PubMed ID: 28598898
[TBL] [Abstract][Full Text] [Related]
18. [Construction of dengue virus-specific full-length fully human antibody libraries by mammalian display technology].
Wen Y; Lan K; Wang J; Yu J; Qu Y; Zhao W; Zhang F; Tan W; Cao H; Zhou C
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):847-52. PubMed ID: 23803195
[TBL] [Abstract][Full Text] [Related]
19. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
20. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591.
Parker SA; Diaz IL; Anderson KA; Batt CA
Protein Expr Purif; 2013 Jun; 89(2):136-45. PubMed ID: 23500147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
